LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Accueil・Liste d'Actions・Exelixis Inc

Exelixis Inc

Fermé

Secteur Soins de santé

25.14 -1.37

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

25.1

Max

25.28

Chiffres clés
By Trading Economics
Revenu	189M 226M
Ventes	212M 637M
P/E Moyenne du Secteur	34.57 103.001
BPA	0.84
Marge bénéficiaire	35.486
Employés	1,310
EBITDA	215M 284M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+11.65 upside

Dividendes
By Dow Jones
Prochains Résultats	30 oct. 2024

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-191M 7.9B
Ouverture précédente	26.51
Clôture précédente	25.14

Sentiment de l'Actualité

By Acuity

50%

114 / 365 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

N/A / 25.7 Support & Résistance

Exelixis Inc Graphique

Actualités Associées

6 sept. 2024, 22:41 UTC

Market Talk

KinderCare and StandardAero File for IPOs -- Market Talk

6 sept. 2024, 21:18 UTC

Actualités

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- Update

6 sept. 2024, 21:05 UTC

Actualités

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 4th Update

6 sept. 2024, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6 sept. 2024, 20:39 UTC

Résultats

Update: NIO Stock Caught an Upgrade. Shares Rose. -- Barrons.com

6 sept. 2024, 20:35 UTC

Actualités

Stocks Extend Ugly Week of Losses Amid Economic Uncertainty -- WSJ

6 sept. 2024, 20:34 UTC

Actualités

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 3rd Update

6 sept. 2024, 20:11 UTC

Actualités

Stock Indexes Close Lower After Mixed Jobs Report -- WSJ

6 sept. 2024, 19:51 UTC

Actualités

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- WSJ

6 sept. 2024, 19:16 UTC

Market Talk

U.S. Natural Gas Futures Hold Gains -- Market Talk

6 sept. 2024, 19:14 UTC

Market Talk

Oil Futures Extend Losses on Demand Concerns -- Market Talk

6 sept. 2024, 19:01 UTC

Market Talk

Gold Slips on Prevailing Uncertainty -- Market Talk

6 sept. 2024, 18:27 UTC

Actualités

JPMorgan Plans to Report Customers Who Exploited TikTok 'Glitch' to Authorities -- WSJ

6 sept. 2024, 18:25 UTC

Market Talk

Broadcom Growth Views Conservative Amid AI Investments -- Market Talk

6 sept. 2024, 18:15 UTC

Actualités

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- Update

6 sept. 2024, 18:12 UTC

Actualités

Nasdaq Falls 2.5%, Leads Losses After Mixed Jobs Report -- WSJ

6 sept. 2024, 17:44 UTC

Market Talk

Labor Costs Represent Diminishing Risk To Canada CPI, CIBC's Shenfeld Says -- Market Talk

6 sept. 2024, 17:30 UTC

Market Talk

U.S Oil Rig Count Unchanged at 483 -- Market Talk

6 sept. 2024, 17:30 UTC

Actualités

Boeing's Starliner Is Returning to Earth Without Its Crew -- WSJ

6 sept. 2024, 17:27 UTC

Actualités

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- WSJ

6 sept. 2024, 17:00 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6 sept. 2024, 17:00 UTC

Market Talk

Mexican Inflation Seen Easing in August -- Market Talk

6 sept. 2024, 16:36 UTC

Market Talk

Oil Futures Fall as U.S. Jobs Report Sinks In -- Market Talk

6 sept. 2024, 16:35 UTC

Résultats

Actions en Tendance

Stocks to Watch Friday: Broadcom, Nvidia, UiPath, Smith & Wesson -- WSJ

6 sept. 2024, 16:33 UTC

Acquisitions, Fusions, Rachats

Salesforce Stock Is on Pace for Longest Losing Streak Since 2008. An Acquisition Isn't Helping. -- Barrons.com

6 sept. 2024, 16:20 UTC

Market Talk

Résultats

Tech, Media & Telecom Roundup: Market Talk

6 sept. 2024, 16:20 UTC

Résultats

Oracle Profit, Revenue Set to Rise in 1Q -- Earnings Preview

6 sept. 2024, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6 sept. 2024, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

6 sept. 2024, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

Comparaison

Variation de prix

Exelixis Inc prévision

Objectif de Prix

By TipRanks

11.65% hausse

Prévisions sur 12 Mois

Moyen 28.08 USD 11.65%

Haut 33 USD

Bas 25 USD

Basé sur 14 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

14 ratings

Achat

Maintien

Vente

Basé sur 14 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

N/A / 25.7Support & Résistance

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

114 / 365Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

EBITDA

Bénéfice d'exploitation

À Propos Exelixis Inc

Exelixis, Inc. is an oncology focused biotechnology company. The Company is engaged in the discovery, development and commercialization of medicines to treat cancers. Its platform also provides therapies to cancer patients with additional treatment options. The Company's cabozantinib molecule, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. The products derived from cabozantinib are CABOMETYX tablets for renal cell carcinoma (RCC) and COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). Its other two product candidates are COTELLIC (cobimetinib), is an inhibitor of MEK with multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO (esaxerenone), is an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) for the treatment of hypertension. Its phase I b clinical trial programs include XL092, STELLAR-001 and STELLAR-002.